Thermo Fisher Scientific and AstraZeneca to Co-Develop NGS-based Companion Diagnostics
Thermo Fisher Scientific and AstraZeneca to Co-Develop NGS-based Companion Diagnostics CARLSBAD, Calif., Sept. 1, 2021 /PRNewswire/ — Thermo Fisher Scientific’s clinical sequencing business and AstraZeneca today announced they will co-develop next-generation sequencing (NGS)-based companion diagnostics (CDx) to support AstraZeneca’s expanding portfolio of targeted therapies. The companies will collaborate under a multiyear, global agreement. “As the... Read more